drug adverse effects of alpha-1 adrenergic receptor antagonists
Jump to navigation
Jump to search
Adverse effects
- dizziness, light-headedness, orthostatic hypotension
- tamsulosin (Flomax) least likely to cause orthostatic hypotension
- alfuzosin (Uroxatral) least likely to cause abnormal ejaculation
- adverse ocular effects
- blurred vision
- eye pain
- risk of intraoperative floppy-iris syndrome during cataracts surgery (most frequent with tamsulosin)
- do not initiate alpha-1 adrenergic receptor antagonist therapy prior to scheduled cataract surgery[4]
- none are likely to cause erectile dysfunction
- worsening chronic renal failure with progression to ESRD[5]
- stress urinary incontinence, especially in women with pelvic organ prolapse[4]
* not associated with increased risk of cardiovascular events in contrast to findings of ALLHAT study[5]
More general terms
References
- ↑ Prescriber's Letter 10(9):53 2003
- ↑ Prescriber's Letter 19(5): 2012 Drug-Induced Adverse Eye Effects Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=280508&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 3.2 Welk B et al The risk of fall and fracture with the initiation of a prostate- selective alpha antagonist: a population based cohort study. BMJ 2015;351:h5398 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26502947 <Internet> http://www.bmj.com/content/351/bmj.h5398
- ↑ 4.0 4.1 4.2 Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022 - ↑ 5.0 5.1 5.2 Hundemer GL, Knoll GA, Petrcich W et al. Kidney, cardiac, and safety outcomes associated with alpha-blockers in patients with CKD: A population-based cohort study. Am J Kidney Dis 2021 Feb; 77:178. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32920153 https://www.ajkd.org/article/S0272-6386(20)30937-9/fulltext